Patent application EP19169121A (EP), filed 2019-04-12
Publication number: EP3722434A1
Title: PLASMID SYSTEM
Abstract: [0001]    The present invention relates to two-plasmid systems, helper plasmids, and/or vector plasmids for producing recombinant AAV (rAAV) vectors. The invention further relates to methods using, or uses of, the two-plasmid systems, helper plasmids and/or vector plasmids of the invention.
IPC codes: C12N  15/    86            A I
Claims: number: 1
text: A helper plasmid comprising:
number: 2
text: A two-plasmid system comprising the helper plasmid of claim 1 and a vector plasmid, wherein the helper plasmid comprises at least one rep gene encoding at least one functional Rep protein and does not comprise a cap gene encoding a functional set of Cap proteins.
number: 3
text: The two-plasmid system or helper plasmid of claim 1 or 2, wherein the helper plasmid comprises at least one rep gene encoding at least one functional Rep protein.
number: 4
text: The two-plasmid system of claim 2 or 3, wherein:
number: 5
text: The two-plasmid system or helper plasmid of any one of the preceding claims wherein:
number: 6
text: The two-plasmid system any one of claims 2-5, wherein:
number: 7
text: The two-plasmid system of any one of claims 4-6, wherein:
number: 8
text: A host cell comprising the two-plasmid system or the helper plasmid of any one of the preceding claims.
number: 9
text: Use of the two-plasmid system, the helper plasmid or the vector plasmid as defined in any one of claims 1-7 for:
number: 10
text: The use of claim 9, wherein the use comprises transfecting a host cell with the two-plasmid system or the helper plasmid of any one of claims 1-7 and culturing the host cell under conditions suitable for recombinant AAV production.
number: 11
text: A method for:
number: 12
text: The method of claim 11:
number: 13
text: A recombinant AAV preparation obtainable by the method of any one of claims 10-12.
Office action: search_report, dated 2020-10-14
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: WO2016181123A1
ref_type: patent
severity: background
ref_id: WO2013029030A1
ref_type: patent
severity: background
ref_id: WO2017096164A1
ref_type: patent
severity: background
ref_id: WO2016075473A2
ref_type: patent
severity: background
ref_id: WO2013078400A1
ref_type: patent
severity: background
ref_id: US7208315B2
ref_type: patent
severity: background
ref_id: WO2015038958A1
ref_type: patent
severity: background
ref_id: - NEHLSEN, K.; BROIL S.; BODE, J., GENE THER. MOL. BIOL., vol. 10, 2006, pages 233 - 244
ref_type: npl
severity: background
ref_id: - KAY, M.A.; HE, C.-Y; CHEN, Z.-H., NATURE BIOTECHNOLOGY, vol. 28, 2010, pages 1287 - 1289
ref_type: npl
severity: background
ref_id: - NAFISSI N; ALQAWLAQ S; LEE EA; FOLDVARI M; SPAGNUOLO PA; SLAVCEV RA, MOL THER NUCLEIC ACIDS, vol. 3, 2014, pages e165
ref_type: npl
severity: background
ref_id: - D.J. PEREIRA; N. MUZYCZKA, J. VIROL., vol. 71, 1997, pages 1747 - 1756
ref_type: npl
severity: background
ref_id: - XIAO ET AL., J. VIROL, vol. 72, 1998, pages 2224 - 2232
ref_type: npl
severity: background
ref_id: - MCCARTY, D. M. ET AL., J. VIROL., vol. 68, no. 8, 1994, pages 4988 - 4997
ref_type: npl
severity: background
ref_id: - MCINTOSH J. ET AL., BLOOD, vol. 121, no. 17, 25 April 2013 (2013-04-25), pages 3335 - 44
ref_type: npl
severity: background
ref_id: - NATHWANI ET AL., BLOOD, vol. 107, no. 7, 1 April 2006 (2006-04-01), pages 2653 - 2661
ref_type: npl
severity: background
ref_id: - MIAO ET AL., MOL THER., vol. 1, 2000, pages 522 - 532
ref_type: npl
severity: background
ref_id: - OKUYAMA ET AL., HUMAN GENE THERAPY, vol. 7, 1996, pages 637 - 645
ref_type: npl
severity: background
ref_id: - WANG ET AL., PROC NATL ACAD SCI USA., vol. 96, no. 7, 30 March 1999 (1999-03-30), pages 3906 - 3910
ref_type: npl
severity: background
ref_id: - "Genbank", Database accession no. AF043303
ref_type: npl
severity: background
ref_id: - YANISCH-PERRON ET AL., GENE, vol. 33, 1985, pages 103 - 119
ref_type: npl
severity: background
ref_id: - WOBUS ET AL., J VIROL, vol. 74, 2000, pages 9281 - 9293
ref_type: npl
severity: background
ref_id: - VERENA V. EMMERLING ET AL: "Rational plasmid design and bioprocess optimization to enhance recombinant adeno‐associated virus (AAV) productivity in mammalian cells", BIOTECHNOLOGY JOURNAL, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 11, no. 2, 24 September 2015 (2015-09-24), DE                                                                                                                                                                                                      , pages 290 - 297, XP072400776, ISSN: 1860-6768, DOI: 10.1002/biot.201500176
ref_type: npl
severity: background
ref_id: - GRIMM ET AL.: "Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6", MOLECULAR THERAPY, vol. 7, no. 6, 2003, XP002256403, DOI: 10.1016/S1525-0016(03)00095-9
ref_type: npl
severity: background
ref_id: - MERTEN ET AL.: "Current issues in adeno-associated viral vector production", GENE, vol. 12, 2005, pages S51 - S61, XP037774007, DOI: 10.1038/sj.gt.3302615
ref_type: npl
severity: background
ref_id: - OGASAWARA ET AL.: "Efficient Production of Adeno-associated Virus Vectors Using Split-type Helper Plasmids", JPN. J. CANCER RES., vol. 90, 1999, pages 476 - 483, XP055572245, DOI: 10.1111/j.1349-7006.1999.tb00772.x
ref_type: npl
severity: background
ref_id: - WRIGHT J. F.: "Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment", BIOMEDICINES, vol. 2, 2014, pages 80 - 97, XP055182498, DOI: 10.3390/biomedicines2010080
ref_type: npl
severity: background
ref_id: - MERTEN O-W.: "AAV vector production: state of the art developments and remaining challenges", CELL & GENE THERAPY INSIGHTS, vol. 2, no. 5, 2016, pages 521 - 551, XP055649764, DOI: 10.18609/cgti.2016.067
ref_type: npl
severity: background
ref_id: - FARRIS K. DAVID, PINTEL DAVID J.: "Improved Splicing of Adeno-Associated Viral (AAV) Capsid Protein-Supplying Pre-mRNAs Leads to Increased Recombinant AAV Vector Production", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 19, no. 12, 1 December 2008 (2008-12-01), GB                                                                                                                                                                                                      , pages 1421 - 1427, XP093113129, ISSN: 1043-0342, DOI: 10.1089/hum.2008.118
ref_type: npl
severity: background
ref_id: US2005080027A1
ref_type: patent
severity: background
ref_id: US2003103939A1
ref_type: patent
severity: background
ref_id: CN108048483A
ref_type: patent
severity: background
ref_id: US2003103939
ref_type: patent
severity: novelty_destroying
ref_id: US2005080027
ref_type: patent
severity: novelty_destroying
ref_id: CN108048483
ref_type: patent
severity: background
Final disposition: pending (2020-10-14)